Roman Kasianov

Director, Head of Content at BiopharmaTrend    

Biotech business developer with a foundation in psychology and PR. Facilitating collaborations, connecting innovation with effective communication in publishing and analytics.

Author in
Marketing & E-commerce   AI & Digital   Bioeconomy & Society   Startups & Deals   NeuroTech   Clinical Trials   Biotech   Manufacturing & Pharma 4.0   Tools & Methods   HealthTech   Aging & Longevity   Contract Research   Novel Therapeutics  


Recent articles from Roman

Nurix Debuts Foundation Model to Predict Novel Binders for Undruggable Targets

   302
Nurix Debuts Foundation Model to Predict Novel Binders for Undruggable Targets

Nurix Therapeutics presented new data at the 2025 AACR Annual Meeting supporting the capabilities of its DEL-AI platform—a machine learning–powered system designed to accelerate discovery of small molecule binders using DNA-encoded library (DEL) data. According to Nurix, its DEL Foundation Model can predict novel binders to a wide range of therapeutically relevant targets, including proteins historically considered undruggable.

NIH Launches Initiative to Prioritize Human-Based Research Technologies

   205
NIH Launches Initiative to Prioritize Human-Based Research Technologies

The National Institutes of Health (NIH) has launched a new initiative to expand the use of human-based research technologies while reducing reliance on animal models, establishing a dedicated Office of Research Innovation, Validation, and Application (ORIVA) to coordinate these efforts across its biomedical portfolio. 

The initiative aims to scale non-animal methods—organoids, tissue chips, computational models, and real-world data analysis—while increasing funding, training, and infrastructure to support their widespread adoption.

Tempus Introduces Loop, an AI-Driven Platform for Target Discovery and Validation

   236
Tempus Introduces Loop, an AI-Driven Platform for Target Discovery and Validation

Tempus AI, Inc. (NASDAQ: TEM) announced the launch of Tempus Loop, a proprietary oncology-focused platform designed to streamline target discovery and validation by integrating real-world patient data (RWD), human-derived biological models, and high-throughput CRISPR-based functional screens. 

The platform aims to address persistent challenges in translating preclinical findings into successful patient treatments, an area where the industry still sees a 90% failure rate.

Potato Lands $4.5M to Automate Lab Work with AI and Robots

   410
Potato Lands $4.5M to Automate Lab Work with AI and Robots

Seattle-based startup Potato has raised $4.5 million in seed funding to accelerate development of its AI platform for automating scientific research. The company, founded in 2023 by neuroscientist Nick Edwards and technologist Ryan Kosai, is developing agent-driven systems to support a closed-loop model of science—from hypothesis generation to experimental execution and analysis.

The company name references the potato battery experiment—a nod to building complex tools from simple foundations.

Tempus, AstraZeneca, and Pathos Partner to Build Oncology Foundation Model Using Multimodal Data

   501
Tempus, AstraZeneca, and Pathos Partner to Build Oncology Foundation Model Using Multimodal Data

Tempus has announced new multi-year agreements with AstraZeneca and Pathos AI to co-develop what is described as the largest multimodal foundation model in oncology. 

The model will be trained on Tempus’ de-identified oncology datasets and is intended to support research across biological insight generation, target discovery, and therapeutic development. All three partners will have access to the resulting model for use in their respective R&D efforts. The deal includes $200 million in combined fees for data licensing and model development.

Elix and PRISM BioLab Partner to Tackle Hard-to-Drug Protein Targets with AI

   369
Elix and PRISM BioLab Partner to Tackle Hard-to-Drug Protein Targets with AI

Elix and PRISM BioLab have announced a partnership aimed at advancing drug discovery for protein-protein interaction (PPI) targets—an area long considered difficult to address with small molecules. The collaboration brings together Elix’s AI-driven compound design capabilities and PRISM BioLab’s small molecule scaffolds that mimic structural motifs found in intracellular protein interfaces.

Finalists Announced for $10M Coller Dolittle Challenge on AI-Powered Interspecies Communication

   309
Finalists Announced for $10M Coller Dolittle Challenge on AI-Powered Interspecies Communication

The Coller Dolittle Challenge has announced its shortlist of four research teams competing for its inaugural $100,000 annual prize, part of a long-term effort to develop scientifically rigorous models of two-way interspecies communication using artificial intelligence. 

Backed by the Jeremy Coller Foundation and administered by Tel Aviv University, the challenge offers a $10 million Grand Prize to any team that achieves sustained, autonomous communication with a non-human species—defined as an animal initiating communication independently, without recognizing the presence of a human recipient.